Combined beta- and Auger electron therapy using a novel somatostatin receptor subtype 2 antagonist labelled with terbium-161 (161Tb-DOTA-LM3) - a phase 0/ phase I study
Research Project | 01.01.2022 - 31.12.2025
|
01.01.2022
- 31.12.2025
Funding
Combined beta- and Auger electron therapy using a novel somatostatin receptor subtype 2 antagonist labelled with terbium-161 (161Tb-DOTA-LM3) – a phase 0/ phase I study
SNF Projekt (GrantsTool), 01.2022-12.2025 (48)
PI : Wild, Damian.CI : Schibli, Roger.
Members (2)
Damian Wild
Principal Investigator